share_log

Regulus Therapeutics Q2 EPS $(0.17) Misses $(0.13) Estimate

Regulus Therapeutics Q2 EPS $(0.17) Misses $(0.13) Estimate

regulus therapeutics第二季度每股收益爲$(0.17),低於$(0.13)的預期。
Benzinga ·  08/09 05:34

Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.13) by 30.77 percent. This is a 54.05 percent increase over losses of $(0.37) per share from the same period last year.

Regulus Therapeutics(納斯達克:RGLS)報告每股虧損$(0.17),比分析師共識預期的$(0.13)低了30.77%。這是與去年同期每股虧損$(0.37)相比增加了54.05%。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論